linjc16/ctgov huggingface dataset:
Endometrial Priming for Embryo Transfer

Study Overview
=================
Brief Summary
-----------------
The aim of this trial is compare two different endometrial priming protocols women that receive oral estrogens women that receive transdermal estrogens

Official Title
-----------------
A Randomised Control Trial to Evaluate Efficacy and Safety of Two Different Protocols of Endometrial Priming for Embryo Transfer.

Conditions
-----------------
Sterility

Intervention / Treatment
-----------------
* Drug: Oral strogen
* Drug: Transdermal strogen


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Women between 18-50 years old with desire of children and needs of embryo transfer. Plasma prolactin less than 30. Uterine cavity that allow pregnancy, body mass index between 20-30. And signed consent inform. Exclusion Criteria: History of estrogen dependent cancer, unknown origin vaginal bleeding. Ovarian cyst. Contraindications to be pregnant. Estrogen allergy.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Oral strogen<br> | Drug: Oral strogen<br>* 2 mg of estradiol every day beginning the second day of the cycle until day 7. 4 mg of estradiol every day beginning 8th day of the cycle until day 10. 6 mg of estradiol every day beginning 11th day of the cycle until day 16.<br>|
| Experimental: Transdermal strogen<br> | Drug: Transdermal strogen<br>* One patch of 75 mcg of estradiol hemimydrate every 48 h from 2 to day 6. Two patches of 75 mcg of estradiol hemimydrate every 48 h from 6 to day 12. Three patches of 75 mcg of estradiol hemimydrate every 48 h from 12 to day 16.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Difference between day means in endometrial priming to achieve 7 mm. |  | 11-16 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Biochemical Pregnancy rate | To calculate the biochemical pregnancy rate, we will divide the number of biochemical pregnancy into the number of embryonary transference and multiply by 100. | 26-30 days | 
| The patient's adherence to the recommended treatment. |  | 1-16 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Oral estrogens, transdermal estrogens, endometrial priming
Evaluation and Physical Therapy for Patients With Degenerated Cervical Spine

Study Overview
=================
Brief Summary
-----------------
The specific aims are as follows: To investigate the degree of impairment, such as range, proprioception, sensation, and electromyography (EMG) pattern of healthy, older subjects. To investigate the relationship of these impairment measurements, the functional outcome and disability in patients with cervical spondylosis. To develop an exercise program with an emphasis on proprioception, stability and coordination for patients with neck-shoulder complaints to decrease the impairment and increase the functions of patients.

Official Title
-----------------
Evaluation and Physical Therapy for Patients With Degenerated Cervical Spine

Conditions
-----------------
Degenerated Cervical Spine, Spinal Diseases

Intervention / Treatment
-----------------
* Behavioral: Therapeutic exercise


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Group one: participants without degenerated disease in the cervical spine Group two: participants with degenerated disease in the cervical spine Exclusion Criteria: Grade III, IV of degenerated cervical spine

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patient with degenerative cervical disease<br> | Behavioral: Therapeutic exercise<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
degenerated cervical spine, assessment, physical therapy
Anti-VEGF Instead of Intraoperative Fan-shaped Photocoagulation in BRVO Combined With Vitreous Hemorrhage

Study Overview
=================
Brief Summary
-----------------
To evaluate the efficacy and safety of Anti-VEGF instead of intraoperative fan-shaped photocoagulation in BRVO combined with vitreous hemorrhage.

Official Title
-----------------
Feasibility Study of Anti-VEGF Instead of Intraoperative Fan-shaped Photocoagulation in BRVO Combined With Vitreous Hemorrhage

Conditions
-----------------
Anti-VEGF, Branch Retinal Vein Occlusion, Vitrectomy

Intervention / Treatment
-----------------
* Procedure: anti-VEGF
* Procedure: fan-shaped photocoagulation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age ≥ 18 years old; BRVO is diagnosed Vitreous hemorrhage Vitreous hemorrhage combined with mild retinal fibrovascular proliferation (early fibrous vascular membrane, thin fibrous vascular membrane, loose retinal adhesion and intact local retinal structure) Exclusion Criteria: BRVO combined with severe retinal fibrovascular proliferation (long-term fibrovascular membrane, thick fibrous vascular membrane and tightly attached to the retina, deformation of local retinal, retinal tear or suspension of retinal vein ) BRVO combined with retinal detachment Retinal veins are completely whitened iris neovascularization or neovascular glaucoma Combined glaucoma combined with other retinopathy Received anti-VEGF treatment within 3 months before surgery

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: anti-VEGF<br>vitreoretinal surgery combined with intraoperative anti-VEGF | Procedure: anti-VEGF<br>* vitreoretinal surgery combined with intraoperative anti-VEGF<br>|
| Active Comparator: fan-shaped photocoagulation<br>vitreoretinal surgery combined with fan-shaped photocoagulation | Procedure: fan-shaped photocoagulation<br>* vitreoretinal surgery combined with intraoperative fan-shaped photocoagulation<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mean change from baseline in best-corrected visual acuity (BCVA) | Assessed using the ETDRS protocol | 3 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mean change from baseline in visual field | Assessed on Humphery(30-2 and 60-4) | 3 years | 
| chang from baseline in structure of retina | Assessed on Optical Coherence Tomography(OCT) | 3 years | 
| chang from baseline in retinal neovascularization | Assessed on Fundus Fluorescein Angiography(FFA) | 3 years |
The Effect of Head and Shoulder Positioning on the Cross-sectional Area of the Subclavian Vein in Obese Adults

Study Overview
=================
Brief Summary
-----------------
In the present study, the cross-sectional area of subclavian vein, and the depth of the SCV from the skin are assessed in different head positions (neutral, rotation to ipsilateral or contralateral sides) and different shoulder positions (neutral or lowered) in spontaneous breathing obese adults.

Official Title
-----------------
The Effect of Head and Shoulder Positioning on the Cross-sectional Area and Location of the Subclavian Vein in Obese Adults

Conditions
-----------------
Normal Volunteers

Intervention / Treatment
-----------------
* Other: Ultrasound assessment of vessels


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy obese adults (BMI ≥ 30) Exclusion Criteria: Medication affecting vascular elasticity History of central venous catheterization or clavicle fracture History of lung surgery, operation of chest cage

Ages Eligible for Study
-----------------
Minimum Age: 19 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Ultrasound assessment of vessels|Subclavian vein and related structures are examined using ultrasonography|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cross-sectional area of subclavian vein | Cross-sectional area of subclavian vein is assessed. | through the completion of assessment, an average of 1 hr | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Depth of subclavian vein from skin | Depth of subclavian vein from skin is assessed. | through the completion of assessment, an average of 1 hr |
Efficacy of TopClosure(C)System in Healing Complicated Pacemaker Wounds

Study Overview
=================
Brief Summary
-----------------
Patients receiving oral anticoagulation or anti-platelet therapy are at high risk of hematoma after device implantation. This study intends to examine the efficacy of the TopClosure(c) System in wound healing in these patients.

Conditions
-----------------
Wounds and Injuries

Intervention / Treatment
-----------------
* Device: TopClosure(c) System
* Device: Pressure Bandage


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients treated with anticoagulant therapy Patients treated with antiplatelet therapy Exclusion Criteria: None

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: TopClosure(c) Treated Wound<br>Pressure Bandage using the TopClosure(C) System | Device: TopClosure(c) System<br> <br> |
| Active Comparator: Traditional Wound Closure Treatment<br>Pressure Bandage | Device: Pressure Bandage<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Efficacy of TopClosure(c) System | Outside surgeon (blinded) will determine whether wound has healed | 10 days |
Open Lung PEEP in Thoracic Surgery

Study Overview
=================
Brief Summary
-----------------
During thoracic surgical procedures, while ventilating with a protective tidal volume, an open lung approach consisting of a recruitment maneuver followed by an individualized positive end-expiratory pressure (PEEP) titrated to best respiratory system compliance (Open-lung PEEP, OL-PEEP) would decrease driving pressure. To test this hypothesis, we performed a multicenter observational study in 17 Spanish teaching hospitals of patients undergoing one lung ventilation (OLV). In addition, we analyzed the association between the driving pressure and the prevalence of postoperative pulmonary complications (PPCs), and finally the association between the individualized PEEP and relevant patient preoperative or intraoperative variables.

Official Title
-----------------
Individualized Open Lung PEEP in Thoracic Surgery: A Prospective Multicenter Observational Study in 17 Spanish Hospitals

Conditions
-----------------
Thoracic Surgery, Ventilation Therapy; Complications

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients undergoing one lung ventilation Exclusion Criteria: No exclusion criteria

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Postoperative pulmonary complications | Atelectasis, acute respiratory failure, ARDS, pneumonia, reintubation, empyema, bronchospasm, pneumothorax, pneumonitis, bronchopleural fistula | Postoperative. One week | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Descriptive analysis of the open lung PEEP | Open lung PEEP is the PEEP of best dynamic respiratory system compliance during a PEEP titration trial | intraoperative |
A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Previously Untreated Metastatic Colorectal Cancer.

Study Overview
=================
Brief Summary
-----------------
This single arm study will assess the efficacy and safety of a combination of modified FOLFIRI (irinotecan, 5-FU and leucovirin), Avastin and cetuximab in patients with previously untreated metastatic colorectal cancer. Patients will receive modified FOLFIRI (irinotecan 180mg/m2 iv, leucovirin 200mg/m2 iv, and 5-FU 400mg/m2 iv) on day 1 of each 2 week cycle, in combination with Avastin (5mg/kg iv on day 1 of each cycle) and cetuximab (loading dose of 400mg/m2 followed by 250mg/m2 on day 3 of each cycle). The anticipated time on study treatment is until disease progression or unacceptable toxicity, and the target sample size is <100 individuals.

Official Title
-----------------
An Open Label Study to Assess the Effect of FOLFIRI Plus Avastin and Cetuximab on Progression-free Survival in Patients With Previously Untreated Metastatic Colorectal Cancer.

Conditions
-----------------
Colorectal Cancer

Intervention / Treatment
-----------------
* Drug: bevacizumab [Avastin]
* Drug: Irinotecan
* Drug: Leucovorin
* Drug: 5 FU
* Drug: Cetuximab


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: adult patients, >=18 years of age; colorectal cancer; advanced or recurrent disease; >=1 measurable lesion; >=6 months since prior adjuvant therapy, and >=4 weeks since prior radiotherapy. Exclusion Criteria: previous treatment for colorectal cancer; significant history of cardiac disease in past 6 months; other invasive malignancy within past 5 years, except for nonmelanoma skin cancer, and successfully treated cervical or prostate cancer.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br> | Drug: bevacizumab [Avastin]<br>* 5mg/kg iv on day 1 of each 2 week cycle<br>Drug: Irinotecan<br>* 180mg/m2 iv on day 1 of each 2 week cycle<br>Drug: Leucovorin<br>* 200mg/m2 iv on day 1 of each 2 week cycle<br>Drug: 5 FU<br>* 400mg/m2 iv on day 1 of each 2 week cycle<br>Drug: Cetuximab<br>* Loading dose of 400mg/m2 iv followed by 250mg/m2 iv on day 3 of each 2 week cycle<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Progression-free survival |  | 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Objective response rate, rate of resection of hepatic metastases, overall survival. |  | Event driven | 
| AEs, laboratory parameters. |  | Throughout study |
Pexelizumab in Conjunction With Angioplasty in Acute Myocardial Infarction (APEX-AMI)

Study Overview
=================
Brief Summary
-----------------
In the setting of reperfusion therapy in an acute myocardial infarction using primary percutaneous intervention (PCI), the body's own inflammatory system involving the complement cascade may be harmful. This study will test the safety and efficacy of a novel complement inhibitor, pexelizumab to reduce mortality at 30 days.

Official Title
-----------------
APEX-AMI - Pexelizumab in Conjunction With Angioplasty

Conditions
-----------------
Acute Myocardial Infarction

Intervention / Treatment
-----------------
* Drug: Pexelizumab
* Drug: Placebo infusion


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Cardiac symptoms for at least 20 minutes within past 6 hours; Will undergo primary PCI; Has ECG evidence of acute high risk ST elevation myocardial infarction; Willing and able to be followed for at least 12 months. Exclusion Criteria: Isolated low risk inferior wall myocardial infarction; Received fibrinolytic therapy; History of complement deficiency; Suspected neisserial infection; Participating in other investigational study; Pregnancy; Previous enrollment.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: 1<br>Placebo infusion | Drug: Placebo infusion<br>* bolus infusion over a 10 minute period once<br>|
| Experimental: 2<br>Pexelizumab infusion | Drug: Pexelizumab<br>* Pexelizumab (2 mg/kg) intravenous , bolus for 10 minutes once<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Reduction of all causes of mortality |  | day 30 |
Clinical Evaluation of 3M™ ESPE™ Adper™ Scotchbond™ SE Self-Etch Adhesive in Class I and Class II Restorations in Adults

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the performance of a new dental adhesive system in the restoration of Class I and Class II cavities in adult teeth.

Official Title
-----------------
Clinical Evaluation of 3M™ ESPE™ Adper™ Scotchbond™ SE Self-Etch Adhesive in Class I and Class II Restorations in Adults

Conditions
-----------------
Dental Caries

Intervention / Treatment
-----------------
* Device: 3M ESPE Adper Scotchbond SE
* Device: 3M ESPE Adper Scotchbond 1XT


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Must be at least 18 years of age Must have 2 or 4 qualifying Class I or Class II cavities Must be willing to sign consent form Must be willing to return to University dental clinic for 4 study appointments Must be in good medical health and able to tolerate dental procedures Exclusion Criteria: Current participation in other restorative product studies Known allergies to dental products Unacceptable level of oral hygiene Chronic periodontitis (gum disease) Rampant caries (cavities) Severe salivary gland problems Inability or unwillingness to attend study appointments

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Adhesive A<br> | Device: 3M ESPE Adper Scotchbond SE<br>* To be used per manufacturer's instructions.<br>* Other names: Dental adhesive used for bonding fillings;|
| Active Comparator: Adhesive B<br> | Device: 3M ESPE Adper Scotchbond 1XT<br>* To be used per manufacturer's instructions.<br>* Other names: Dental adhesive used for bonding fillings;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percentage of Restorations Scoring Alpha | Restorations were scored Alpha, Bravo or Charlie for retention, post-operative sensitivity, anatomic form, margin integrity, color match, stain resistance, and secondary caries. Alpha score = 'excellent' Bravo = 'acceptable' Charlie = 'unsatisfactory'. Total Alpha scores were evaluated for the primary outcome. | 12 months |